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Abstract  
INTRODUCTION: Systemic lupus erythematosus (SLE) and myasthenia gravis (MG) are 
autoimmune diseases that show some similarities: a higher incidence in young women, relapsing-
remitting course and positive anti-nuclear antibodies (ANA). However, they are two different clinical 
syndromes, which can coexist or precede each other. Thymectomy is a therapeutic option for 
patients with severe MG or thymoma. There are many cases of SLE after thymectomy described in 
the literature, so the question arises whether thymectomy predisposes patients to SLE and what 
are imunopathogenetic mechanisms behind this process. 
CASE REPORT: We report a case of a patient who was diagnosed with SLE and secondary 
antiphospholipid syndrome (APS) 28 years after thymectomy for MG. Clinical picture of SLE was 
characterized by cutaneous and articular manifestations, polyserositis, lupus nephritis and 
immunological parameters showed positive ANA, anti-ds-DNA, excessive consumption of 
complement components, positive cryoglobulins. Clinical and laboratory immunological parameters 
for the diagnosis of secondary APS where also present. The patient was initially treated with 
glucocorticoids followed by mycophenolate mofetil. During one year follow-up patient was in a 
stable remission of SLE. 
CONCLUSION: Thymectomy for MG may predispose SLE development in some patients. Further 
studies are needed to better understand the connection between these two autoimmune diseases. 
 
 
 
 
 
 
 
Introduction 
 
Systemic lupus erythematosus (SLE) is a 
systemic autoimmune disease characterized by 
multiorgan dysfunction, production of numerous 
autoantibodies and higher incidence in women of 
childbearing age. Myasthenia gravis (MG) is an organ-
specific autoimmune disease characterized by 
dysfunction of the neuromuscular junction mediated 
by autoantibodies directed to: the nicotinic 
acetylcholine receptor (nAChR), the muscle specific 
tyrosine kinase (MuSK) or the low-density 
lipoproteinreceptor-related protein 4 (LRP4) with the 
consequent muscle weakness [1, 2]. In regard to the 
clinical picture, type of autoantibodies present, age of 
the patient at the diagnosis and thymus pathology, 
patients with MG can be classified into different 
subgroups. Therapeutic modalities include use of 
immunosuppressive drugs, supportive therapy and 
thymectomy [3]. Thymectomy is a therapeutic option 
for patients with non-thymomatous MG, as well for 
patients with thymoma regardless of the severity of 
MG (3). 
The literature describes cases of SLE after 
thymectomy, but pathogenetic mechanisms that lead 
to this phenomenon are not clear. We present a case 
of a patient who was diagnosed with SLE and 
secondary APS 28 years after thymectomy performed 
for MG. 
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Case report 
 
A 48 years old female patient was admitted to 
the Clinic for Allergy and Immunology under suspicion 
of systemic connective tissue disease. The main 
complaints were marked fatigue, photosensitivity, 
hives, swelling and pain in the small joints of hands, 
wrists and ankles, Raynaud’s phenomenon. About 
seven months before admission the patient was 
treated at the regional hospital for pulmonary 
embolism and exudative pericarditis. Three years 
before admission she was examined by a 
hematologist due to generalized lymphadenopathy, 
and after a detailed examination a lymphoproliferative 
disorder was ruled out. Her past medical history 
revealed that she underwent thymectomy for 
generalized form of MG 28 years ago, after which a 
complete long-term remission was achived.  
Physical examination on admission showed 
hives, generalized lymphadenopathy, cyanotic lips, 
spontaneous Raynaud's phenomenon on fingers, 
acute synovitis of proximal interphalanegal and 
metacarpophalangeal joints and wrists, and 
perimaleolar pitting edema. Other physical findings 
were normal. Laboratory studies showed marked 
inflammatory syndrome, elevated total serum proteins, 
hypoalbuminemia, elevated serum alkaline 
phosphatase, G-glutamyl transferase, lactate 
dehydrogenase. Granulated cylinders were seen in 
the urine sediment, with 24h-proteinuria of nephrotic 
range and slightly reduced creatinine clearance. The 
result of blood gas analysis was normal. 
Immunoserological analysis showed positive ANA on 
a substrate of HEp2 cells (indirect 
immunofluorescens) in a dilution higher than 1: 640 
homogeneous type of staining, positive anti-dsDNA 
and anti-cardiolipin antibodies (both IgG and IgM 
type), presence of cryoglobulins, with marked signs of 
complement activation. Serum immunoglobulins levels 
were extremely high. Direct Coombs test was positive, 
but there were no other laboratory or clinical signs of 
active haemolysis. 
Table 1 shows the results of laboratory and 
immunological analysis at the diagnosis of SLE and 
secondary APS. 
A minor pleural effusion on the right side and 
exudative pericarditis were seen on the chest 
radiography. Lupus Band Test (LBT) was positive. 
Abdominal sonography showed an enlarged liver (166 
cm). Echocardiography demonstrated pronounced 
enlargement of the right heart, with 4 + tricuspid 
regurgitation, pericardial effusion around the entire 
heart, enlarged pulmonary vein and paradoxical 
movement of the septum, left atrium collapsed during 
diastole, the pressure in the right ventricle was 
estimated at 100 mm Hg. Multislice CT pulmonary 
angiography was normal. 
Table 1: Laboratory and immunoserological analysis of the 
patient with SLE and APS after thymectomy for MG 
Analysis Normal values Finding 
ESR (1h ) (mm/h) 2 - 10 68 
C-reactive protein  (mg/l) 0 - 5 30 
Leukocytes (x 10
9
/l) 3.5 – 10 8.0 
Neutrophils  (x 10
9
/l) 2.1 – 6.5 4.0 
Hemoglobin (g/l) 122 – 157 142 
Erythrocytes (x 10
12
/l) 3.86 – 5.08 4.9 
MCV (fl) 83 - 97 88 
Urea (mmol/l) 2.8 – 7.2 6.7 
Creatinine ( µmol/l) 58 – 96 92 
Aspartate aminotransferase (U/l) 0 – 31 30 
Alanine aminotransferase (U/l) 0 - 34 28 
Total serum proteins (g/l) 66 - 83 84 
Albumines (g/l) 35 - 53 29 
G-glutamyl-transferase (U/l) 4- 32 93 
Lactate dehydrogenase (U/l) 0 - 247 729 
Alkaline phosphatase (U/l) 30 - 120 214 
Creatinine clearance (ml/min) 87 -107 68.7 
Urine cylinders (cells/HPF) 0 -2 hyaline 
cylinders 
3-4 granulated cylinders 
24h-proteinuria 0.05 – 0.150 6.8 g/24h 
ANA Hep2 – IIF negative >1:640 homogenous type of 
staining 
Anti-ds-DNA negative 1:40 
Anticardiolipin Ab IgG (ELISA) (GPL-
U/ml) 
0 – 12 47.1 
Anticardiolipin Ab IgM (ELISA) (MPL-
U/ml) 
0 - 12 93.4 
Cryoglobulins negative +++ 
Complement C3 (g/l) 0.9 – 2.07 1.17 
Complement C4 (g/l) 0.12 – 0.36 0.08 
IgG (g/l) 6.5 – 16 > 30 
IgM (g/l) 0.5 – 3 > 6 
IgA (g/l) 0.4 – 3.5 2.82 
Coombs test (anti-IgG) negative ++ 
 
ESR – erythrocyte sedimentation rate; MCV – mean corpuscular volume; Ig – 
immunoglobulin. 
 
The diagnosis of SLE was made based on the 
following criteria of the American College of 
Rheumatology (6/11): photosensitivity, polyarthritis, 
polyserositis (pericardial and pleural effusion), renal 
lesions (abnormal urine sediment, nephrotic rank 
proteinuria), positive ANA, anti-dsDNA and anti-
cardiolipin antibodies. The diagnosis of secondary 
antiphospholipid syndrome was based on the Sapporo 
criteria: pulmonary embolism and positive 
anticardiolipin antibody IgG and IgM type on two 
occasions for a period longer than 12 weeks. 
 The patient was treated using glucocorticoid (initialy 
methyl-prednisolon 1 mg/kg body weight, followed by 
three 'pulse' doses of methyl-prednisolone, each 
1,000 mg) and anticoagulant therapy with favorable 
clinical and laboratory response. In the further course, 
a renal biopsy was performed and pathohistological 
examination revealed diffuse proliferative 
glomerulonephritis. Mycophenolate mofetil therapy 
was introduced at a dose of 2 grams orally with oral 
prednisone therapy. During the one-year follow-up 
period patient was in a stable remission of SLE. 
 
 
Discussion 
 
Systemic lupus erythematosus and 
myasthenia gravis are autoimmune diseases that 
share some similarities. They occur more often in 
women, the clinical course is characterized by periods 
of exacerbation and remission and both share 
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positivity for antinuclear antibodies [4]. It is known that 
patients who are affected by one autoimmune disease 
are at increased risk of developing the second one. 
The frequency of second autoimmune disease is 13 – 
22 % in patients with MG [5-8]. Large population 
based nested case-control study of Swedish authors, 
analyzing 2045 MG cases, has showed the presence 
of other autoimmune diseases in 449 (22.0%) 
patients, most commonly hypothyroidism, rheumatoid 
arthritis, type I diabetes, and psoriasis. The patients 
with MG had higher prevalence of other autoimmune 
disease compared to a control group of general 
population [8]. On the other hand, the development of 
MG in SLE patients is rarely reported. In a study of 
Canadian authors who followed 380 patients with SLE 
over a period of 9 years, the diagnosis of MG was 
established only in one patient [9]. The possible 
explanation may be that in SLE patients, the muscle 
weakness may be considered as a complication of 
glucocorticoid therapy (glucocorticoid myopathy) 
rather than a symptom of MG. Therefore, MG should 
be included in the differential diagnosis of SLE 
patients with muscle weakness [7]. These data 
suggest that SLE and MG are two distinct 
autoimmune diseases that may coexist, but the 
immunopathogenic basis of this association is not yet 
clear. It is possible that they both share certain 
common genetic, immunological and environmental 
factors that may be important in the pathogenesis of 
both disorders [10]. 
In the literature, the appearance of SLE after 
thymectomy for MG is documented mainly in case 
reports. In 1994 the group of Greek authors described 
a patient who was diagnosed with SLE 6 years after 
thymectomy that was performed for MG [11]. The 
French authors have concluded that development of 
SLE after thymectomy or thymomectomy may be 
more than a coincidence [12]. The SLE development 
after thymectomy for MG is described in two case 
reports of Korean authors [13]. In one patient, SLE 
has developed three months after thymectomy, while 
in the other patient 13 years after thymectomy. The 
main clinical manifestation of SLE in both patients was 
polyarthritis.The group of Italian authors have followed 
the long-term immunological effects after thymectomy 
in patients with MG [14]. There were 16 patients who 
underwent thymectomy at least 8 years before the 
study and the results were compared to a group of 
recently thymectomized and non-thymectomized 
patient with MG [14]. Patients who underwent 
thymectomy for more than 8 years had elevated 
serum IgG, IgM, anticardiolipin, anti- dsDNA 
antibodies and mild T - cell lymphopenia. After three 
years of follow-up, two of these 16 patients were 
diagnosed with systemic autoimmune diseases, one 
with SLE and other with undifferentiated connective 
tissue disease. 
These data indicate that in some patients with 
MG who undergo thymectomy, SLE may develop over 
the years. The mechanisms behind this process are 
not completely understood, and the role of 
thymectomy itself is considered as the possible 
precipitating factor in the process of SLE 
development. The studies on experimental models 
suggest the development of autoimmune diseases 
after thymectomy [15, 16]. Thymus plays an important 
role in maintaining immune homeostasis through the 
processes of central tolerance that may be affected by 
pathological processes in it (hyperplasia, thymoma). It 
is possible that thymectomy can lead to imbalance of 
autoreactive and regulatory T cells and to the initiation 
of autoimmune processes due to the loss of central 
tolerance and excessive production of autoantibodies. 
Thymectomy may create conditions for the sequence 
of events that, in genetically predisposed individuals, 
can lead to development of SLE, in associations with 
environmental factors [13, 14]. 
In our case report, SLE was diagnosed 28 
years after thymectomy that was performed for MG 
and and by which long-term remission of MG was 
achived. The main clinical SLE manifestations in our 
patient were diffuse proliferative lupus nephritis with 
nephrotic proteinuria. Our patient was also diagnosed 
with secondary APS. Systemic lupus erythematosus 
with lupus nephritis as the leading clinical 
manifestation after thymectomy is described in a case 
report by Lee and associates, although there was no 
pathohistological confirmation of lupus nephritis 
because the patient refused a kidney biopsy [10]. In 
other case reports in the literature, the most common 
clinical feature of SLE after thymectomy is 
polyarthritis, and to a lesser extent cytopenia , 
pleuritis, skin changes [13]. To our knowledge, the 
case of SLE with severe lupus nephritis and 
secondary APS after thymectomy for MG was not 
previously described in the literature. 
Although the data from the literature suggest 
the coexistence of SLE and MG, the pathological 
mechanisms behind these association are not fully 
known, as well as potential triggers that can lead to 
the development of SLE in MG patients and vice 
versa. In this sense, Bhinder and associates have 
posed an intriguing question: are these two diseases 
part of the same autoimmune disease spectrum; 
which of these diseases is more likely to predispose to 
the development of the other and why? [17]. The 
literature data suggest that SLE can occur after 
thymectomy, so an interesting question emerges: is 
the thymectomy risk factor, rather than a possible 
predisposing factor for the SLE development in some 
patients? If so, whether patients with MG after 
thymectomy show some clinical characteristics that 
may indicate SLE diagnosis? How regularly they 
should be evaluated for the possible diagnosis of 
SLE? 
In conclusion, the association between SLE 
and MG is complex. These two autoimmune diseases 
may precede one another or coexist. Thymectomy 
may be a precipitating factor that over time period can 
lead to the development of SLE in certain individuals. 
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Therefore, in MG patients who have undergone 
thymectomy, any clinical and immune serological SLE 
suspicion should be carefully evaluated.  
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